Previous 10 | Next 10 |
KemPharm press release ( NASDAQ: KMPH ): Q2 Non-GAAP EPS of -$0.19 misses by $0.05 . Revenue of $1.3M (-89.2% Y/Y) misses by $0.45M . As of June 30, 2022, total cash, cash equivalents and investments were $114.5 million, which was a decrease of $4.6 million com...
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET Perry Sternberg, Corium, Inc.’s President and CEO, to Participate and Provide Update on the Commercialization of AZSTARYS ® Acquired s...
CELEBRATION, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative a...
CELEBRATION, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative a...
CELEBRATION, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative an...
A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...
Gainers: Cortexyme (CRTX) +7.9%. GoodRx Holdings (GDRX) +5.4%. Concert Pharmaceuticals (CNCE) +4.9%. Roku (ROKU) +4.3%. Mercer International (MERC) +4.3%. Losers: Rhythm Pharmaceuticals (RYTM) -8.5%. Redbox Entertainment (RDBX) -3.6%. KemPharm (KMPH) -3.1%. SS&C Technologies Hol...
Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related effects compared to d-MPH CELEBRATION, Fla., June 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (K...
Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with...
KemPharm, Inc. (KMPH) Q1 2022 Earnings Conference Call May 12, 2022, 17:00 ET Company Participants Travis Mickle - Co-Founder, President, CEO & Director LaDuane Clifton - CFO, Secretary & Treasurer Conference Call Participants Jason Rando - Tiberend Strategic Advisors Presentation Ope...
News, Short Squeeze, Breakout and More Instantly...
CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Org...
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission...
CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:3...